Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review.
Fiche publication
Date publication
août 2022
Journal
Clinics and research in hepatology and gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Neuzillet C, Malka D, Lièvre A, Khurana IS, Vernerey D
Lien Pubmed
Résumé
Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints for phase II trials. However, the ultimate goal is to bring survival benefit for the patients. We aimed to assess the correlation between ORR, median PFS and overall survival (OS) using aggregated data from a systematic review of second-line systemic therapies in advanced biliary tract cancer (BTC) patients.
Mots clés
BTC, Biliary Tract Cancer, CI, Confidence Interval, CR, Complete Response, Chemotherapy, cholangiocarcinoma, endpoint, correlation, targeted therapy, FGFR, Fibroblast Growth Factor Receptor, HRQoL, Health-Related Quality of Life, IDH, Isocitrate Dehydrogenase, ORR, Overall Response Rate, OS, Overall Survival, PFS, Progression-Free Survival, PS, Performance Status, RECIST, Response Evaluation Criteria in Solid Tumors, eCCA, Extrahepatic Cholangiocarcinoma, iCCA, Intrahepatic Cholangiocarcinoma
Référence
Clin Res Hepatol Gastroenterol. 2022 08 18;:102010